Cabinet of Ministers Regulations No. 574 Riga, July 21, 2008 (pr. No 51 35) amendment to the Cabinet on 19 July 2005, the provisions of the "rules on no 528 national agency" infektoloģij Center "public service price list" Issued in accordance with the law on budget and financial management of the ninth paragraph of article 5 to make a Cabinet of 19 July 2005, the provisions of the "rules on no 528 national agency" infektoloģij Center "public service price list" (Latvian journal, 2005, 115 No; 2006, 2007 101 no; 88. No.) amendments and express attachment as follows: "Cabinet of Ministers on 19 July 2005, regulations No 528 national agency" infektoloģij Center "public service price list no PO box
The type of service the unit price without VAT (Ls) excluding VAT (Ls) price with VAT (Ls) (I). the public services on which the associated costs shall not be covered from the State budget of 1.
Vaccination and the preparation of 1.1 imūnbioloģisk.
vaccination against tick encephalitis for 1.1.1.
vaccination against tick encephalitis (adults) 1 vaccination 16.00 0 16.00 1.1.2.
vaccination against tick encephalitis (children) 1 vaccination 15.50 0 15.50 1.2.
pretērč encephalitis immunoglobulin infusion 1 vaccination 10.30 0 10.30 1.3.
vaccination against rabies vaccination 12.00 12.00 1 0 1.4.
vaccination against yellow fever vaccination 0 1.5 1 16.30 16.30.
vaccination against viral hepatitis in 1.5.1.
vaccination against viral hepatitis A (adults) 1 vaccination 20.40 0 20.40 1.5.2.
vaccination against viral hepatitis A (child) 1 vaccination 17.70 0 17.70 1.5.3.
vaccination against viral hepatitis B (adults) 1 vaccination 10.00 0 10.00 1.5.4.
vaccination against viral hepatitis B (children) 1 vaccination 7.60 0 7.60 1.5.5.
vaccination against viral hepatitis A and viral hepatitis B (combined vaccine in a single dose) 1 vaccination 29.00 0 29.00 1.6.
vaccination against chickenpox vaccination 28.00 28.00 for 1 0 1.7.
vaccination against typhoid fever vaccination 11.00 11.00 1 0 1.8.
vaccination against polio, diphtheria, kind of cramps 1 0 9.00 9.00 vaccination 1.9.
vaccination against meningococcal infection 1 vaccination 11.70 0 11.70 1.10.
vaccination against pneumococcal infection 1 vaccination 13.00 0 13.00 1.11.
vaccination against influenza is 1.11.1.
vaccination against the flu (adults) 1 vaccination 6.00 0 6.00 1.11.2.
vaccination against flu (children) 1 vaccination 5.00 0 5.00 1.12.
vaccination against cholera vaccination 21.00 1 0 21.00 1.13.
vaccination against epidemic of mumps, measles, rubella vaccination 10.00 1 0 10.00 1.14.
international certificate of vaccination or booster vaccination against yellow fever certificate 0.60 0.11 0.71 1 1.15.
off-site vaccination 1.15.1.
vaccinations work collective (up to 50 people) 1 sail 12.00 12.00 0 1.15.2.
vaccinations work collective (51-100 people) 1 sail 22.00 0 22.00 1.15.3.
vaccinations work collective (101-200) 1 sail 32.00 32.00 0 1.15.4.
vaccinations work collective (201-300) 1 0 42.00 42.00 sail 2.
Dentist Services ** 2.1.
dentist and first-time history data collection study 4.10 4.10 0 1 2.2.
dentist was six months after the study 1 0 2.05 2.05 2.3.
determination of tooth vitality one tooth 1 study 0.70 0 0.70 2.4.
tooth higiēnist of 1 consultation consultation 2.30 0 2.30 2.5.
dentist's written one treatment plan 1 plan 1.80 0 1.80 2.6.
x-ray evaluation of assessment 1 0 1.10 1.10 2.7.
hygiene instruction and motivational instruction 0 1 2.30 2.30 2.8.
the tooth surface treatment with pretkaries feature 1 procedure 0.85 0 0.85 2.9.
the tooth remove fever throughout the soft mouth procedure 1 0 2.95 2.95 2.10.
the old seals into 1 procedure 0.90 0 0.90 2.11.
Tartar removal and polishing (one unit of time) 1 0 5.70 5.70 2.12. procedure
tooth kavitāt and karioz of the mass removal, including the temporary closure of the kavitāt procedure 1 0 4.30 4.30 2.13.
tooth kavitāt creation and indirect pulp capping with calcium hydroxide (Ca (OH) 2), including the temporary closure of the kavitāt procedure 1 0 6.55 6.55 2.14.
kavitāt creation, with composite plombējam material, including the lining of insertion, matrix taxation or other AIDS to the use of seals and seal polishing 2.14.1.
incisīv, one-surface procedure 1 0 8.65 8.65 2.14.2.
incisīv, two surface 1 procedure 10.00 0 10.00 2.14.3.
premolār, one-surface procedure 1 0 8.65 8.65 2.14.4.
premolār, two surface 1 procedure 10.25 0 10.25 2.14.5.
molar, one surface 1 procedure 8.65 0 8.65 2.14.6.
molar, two surface 1 0 12.00 12.00 2.15 procedure.
kavitāt creation, with composite plombējam material, including the lining of insertion, matrix taxation or other AIDS to the use of seals and seal polishing 2.15.1.
incisīv, three surface 1 procedure 13.00 0 13.00 2.15.2.
incisīv, four surface 1 0 18.80 2.15.3 18.80 procedure.
premolār, three surface 1 procedure 22.80 0 22.80 2.15.4.
premolār, four surface 1 procedure 27.35 0 27.35 2.15.5.
Clinical Crown restoration procedure 1 0 2.16 26.20 26.20.
in the teeth of the vital pulpekstirpācij viensakn 1 procedure 7.75 0 7.75 2.17.
pulpekstirpācij divsakņ of the teeth in a vital 1-0 2.18 10.00 10.00 procedure.
pulpekstirpācij trīssakņ of the teeth in a vital 1-0 14.40 2.19 14.40 procedure.
drug insert 1 procedure starpseanso 1.35 0 1.35 2.20.
root canal treatment of tooth viensakn 1 procedure 5.35 0 5.35 2.21.
root canal filling of teeth 1 procedure viensakn 4.20 0 4.20 2.22.
root canal treatment of tooth divsakņ 1 procedure 6.75 0 6.75 2.23.
root canal filling of teeth 1 procedure divsakņ 6.90 0 6.90 2.24.
root canal treatment of tooth trīssakņ (one – two impressions) procedure 11.20 0 1 2.25 11.20.
root canal trīssakņ dental filling procedure 1 0 9.15 9.15 2.26.
root canal of tooth viensakn pārārstēšan of procedure 1 0 9.20 9.20 2.27.
root canal of tooth pārārstēšan divsakņ 1 procedure 10.70 0 10.70 2.28.
root canal of tooth pārārstēšan trīssakņ 1 procedure 0 2.29 13.20 13.20.
endodontisk to open the tooth treated through the Crown procedure 1 0 2.30 3.50 3.50.

viensakn-tooth extraction wound decoration, 1 procedure 0 4.70 2.31 4.70.
daudzsakņ tooth extraction, wounds finish 8.40 procedure 1 0 8.40 2.32.
redirected or thin tooth extraction procedure 1 0 15.25 15.25 2.33.
mucous diseases local drug treatment procedure 1 0 4.65 4.65 2.34.
surface anesthesia procedure 1 0 0.90 0.90 2.35.
infiltration anesthesia procedure 1 0 1.60 2.36 1.60.
District 1 procedure anesthesia 2.30 0 2.30 3.
3.1 the service services.
with treatment related services ** 3.1.1.
Insert a single patient in the ward of 8.00 8.00 1 days 0 3.1.2.
Insert 1 patient days of boxing 0 12.00 12.00 3.1.3.
detoxification of alcohol intoxication and withdrawal to the stationary blending (one day) 1-0 days 29.00 29.00 3.1.4.
detoxification of alcohol intoxication and withdrawal for blending Hospital (two nights) for 2 days of 51.00 0 51.00 3.2.
medical records copying 3.2.1.
the copy has been made with the copy machine for A5 page 0.08 0.01 0.09 3.2.2.
the copy has been made with the copy machine for A4 page 0.15 0.03 0.18 3.2.3.
repeating the statement preparation and after issuing a written request within one week 1 document 3.2.4.3.55 0.64 4.19
repeating the statement preparation and service the next day after receipt of the request 1 document 6.20 1.12 7.32 3.2.5.
extract translation in a foreign language (English, Russian) 1 document 4.80 0.86 5.66 4.
Methodically consultative work 4.1.
laboratory specialist training (with the exception of the epidemiological surveillance laboratory professionals) 1 academic hour 6.25 1.13 7.38 4.2.
training of laboratory methods 1 participant 6.25 1.13 7.38 4.3.
a thematic workshop on laboratory diagnosis (of each member) 1 member 9.40 1.69 11.09 4.4.
Lecture on diagnosis (from each participant) participant 3.10 0.56 3.66 1 4.5.
training vakcinoloģij infektoloģij Centre of Latvia in the vaccination room (from each participant) participant 12.50 2.25 14.75 1 4.6.
methodically advisory work in the prevention of infectious diseases issues 1 study 12.50 2.25 14.75 II. Public services that are provided to a person without a family doctor or specialist referral outpatient or inpatient investigation and treatment 5.
Health care outpatient in Chapter 5.1.
outpatient consultations 5.1.1.
the professor's advice (first inspection) 1 consultation 35.00 35.00 0 5.1.2.
the professor's advice (see again) 1 consultation 20.00 0 20.00 5.1.3.
Assistant Professor counseling (first inspection) 1 consultation 20.00 0 20.00 5.1.4.
Assistant Professor counseling (re view) 1 consultation 15.00 0 15.00 5.1.5.
certified infektolog, therapist, Pediatrics, dermatovenerolog, gynecologist, surgeon, neurologist, hepatolog, psychotherapist, otorinolaringolog consulting (first inspection) 1 consultation 15.00 0 15.00 5.1.6.
certified infektolog, therapist, Pediatrics, dermatovenerolog, gynecologist, surgeon, neurologist, hepatolog, psychotherapist, otorinolaringolog consulting (re view) 1 consultation 10.00 0 10.00 5.1.7.
infektolog consultation tropical disease (at the time) 1 consultation 6.00 0 6.00 5.1.8.
infektolog consultation tropical disease (out of time) 1 7.00 0 to consult 7.00 5.1.9.
okulist inspection and spectacle out 1 study 3.50 0 3.50 5.1.10.
the radiologist consultation 1 3.00 3.00 5.1.11 0 study.
gynecologist, preventive inspection specialist 1 study 7.55 0 7.55 5.1.12.
ophthalmologist preventive inspection 1 study 7.85 0 7.85 5.1.13.
preventive examination 1 otolaringolog study 6.30 0 6.30 5.1.14.
Occupational medical examination 1 study 6.00 0 6.00 5.2.
the injection takes place in 5.2.1.
the skin of the injection 1 0 0.50 0.50 5.2.2 injection.
hypodermic injection 1 0 0.50 0.50 5.2.3 injection.
injection muscle 1 0 0.50 0.50 5.2.4 injection.
injection of vein 1 injection 1.50 1.50 0 5.2.5.
sampling of blood from veins 1 injection 1.00 0 1.00 5.2.6.
vakutainer 1 0 0.15 0.15 6 injection.
Hospital profile patient days (without the most rigorous studies Diagnosta) 1 0 7 days of 30.00 30.00.
Laboratory studies 7.1.
clinical study in 7.1.1.
investigation of blood, unmodified.
White (adding the camera) 1 study 0.46 0.46 0 7.1.1.2.
retikulocīt (manually) study 1 0 1.16 7.1.1.3 1.16.
platelets (manually) study 1 1.04 0 1.04 7.1.1.4.
sink rate of red (EGA) study 1 0 0.76 7.1.1.5 0.76.
Leukocyte formula and erythrocyte morphology study 1 0 1.76 1.76 7.1.1.6.
flowing blood in time after the Duke study methods 1 0 7.1.1.7 0.55 0.55.
Red vilkēd (LED) study of cell 1 0 4.58 4.58 7.1.1.8.
blood test with a three-part Blood analyser 1 discriminatory study 1.73 0 1.73 7.1.1.9.
retikulocīt automated haematology Analyzer with the investigation of the study 1 0 4.66 4.66 7.1.1.10.
blood analysis with five-part Blood analyser 1 discriminatory study 3.00 3.00 0 7.1.1.11.
blood analysis with five-part of the analyser and discriminatory blood red cells sink rate (EG) discovery 1 study 3.76 0 3.76 7.1.1.12.
blood analysis, determination of retikulocīt with five-part of the analyser and discriminatory blood red cells sink rate (EG) discovery 1 8.42 0 8.42 7.1.1.13 study.
blood analysis with five-part of the analyser, the discriminatory blood retikulocīt detection and manual erythrocyte sink rate (EG) discovery 1 study 4.92 0 4.92 7.1.2.
urine investigation 7.1.2.1.
physical examination 1 study 0.16 0.16 0 7.1.2.2.
protein (quantitative) study 1 0 1.24 1.24 7.1.2.3.
quantitative microscopy 1 sediment study 1.45 0 1.45 7.1.2.4.
urine analysis with strip (environmental level (pH), proteins, sugar, acetone, bilirubin, urobilinogēn, blood) 1 0 0.87 0.87 7.1.2.5 study.
analysis of urine with the strip, physical and mikroskopēšan study of sediment 1 0 2.16 2.16 7.1.2.6.
determination of specific weight of urine with 1 urometr study 0.18 0 0.18 7.1.3.
likvor clinical investigation study 1 0 2.35 2.35 7.1.4.
sputum examination 7.1.4.1.
clinical analysis of sputum examination 0 1 1.91 1.91 7.1.4.2.
mikobaktērij the bakterioskopisk enquiry

1 study 2.32 0 2.32 7.1.5.
investigation of faecal 7.1.5.1.
koprogramm 1 the examination 1.82 0 1.82 7.1.5.2.
a study of latent blood 1 0 0.44 7.1.5.3 0.44.
bile pigments 1 study 0.40 0 0.40 7.1.5.4.
hidden blood in the teststrēmel (imūnhromatogrāfij) 1 study 1.10 0 1.10 7.1.6.
the serous cavities and the cyst fluid clinical investigation study 1 0 1.91 1.91 7.2.
biochemical studies 7.2.1.
blood investigation 7.2.1.1.
bilirubin, fractions 1 study 0 1.75 7.2.1.2 1.75
alanīnaminotransferāz 1 the examination 1.41 0 1.41 7.2.1.3.
aspartātaminotransferāz 1 the examination 1.41 0 1.41 7.2.1.4.
alkaline phosphatase 1 study 1.41 0 1.41 7.2.1.5.
Alpha-1 amilāz study 2.35 0 2.35 7.2.1.6.
gamma-glutamiltransferāz 1 the examination 0 1.73 1.73 7.2.1.7.
kreatīnkināz 1 the examination 2.22 0 2.22 7.2.1.8.
urea (bun) study 1 0 1.43 7.2.1.9 1.43.
creatinine 1 study 1.43 0 1.43 7.2.1.10.
uric acid study 1.55 1.55 7.2.1.11 0 1.
protein (total) 1 study 0 1.06 1.06 7.2.1.12.
albumin 0 7.2.1.13 1 study 1.12 1.12.
protein fractions 1 4.36 0 4.36 7.2.1.14 study.
blood glucose study 7.2.1.15 0.97 0.97 0 1.
glucose loading test 1 study 3.31 0 3.31 7.2.1.16.
cholesterol (total) 7.2.1.17 1.46 0 1.46 1 study.
triglycerides 0 7.2.1.18 1 the examination 1.79 1.79.
C-reactive protein (quantitative) study 1 0 2.61 2.61 7.2.1.19.
for 5.12 0 ferritīn 1 study 5.12 7.2.1.20.
antistreptolizīn-0 (quality) of the study 1 0 1.73 1.73 7.2.1.21.
determination of ethanol by enzymatic study 4.50 0 4.50 7.2.1.22 1.
potassium 0 7.2.1.23 1 the examination 1.68 1.68.
sodium 1 study 1.68 0 1.68 7.2.1.24.
calcium 1 study 0 1.43 1.43 7.2.1.25.
study of iron 1 0 1.58 1.58 7.2.1.26.
Iron binding capacity 1 study 2.25 0 2.25 7.2.1.27.
copper in the blood 1 study 2.97 0 2.97 7.2.1.28.
tiroksīn free (FT4) 1 study 4.06 0 4.06 7.2.1.29.
free trijodtiroksīn (FT3) study 1 0 7.2.1.30 4.06 4.06.
the tireotrop hormone (TSH) 1 study 3.93 0 3.93 7.2.1.31.
Reduced Glutathione study 11.98 11.98 7.2.1.32 1 0.
rheumatoid factor (high quality) 1 study 0 1.52 1.52 7.2.1.33.
high density lipoproteins (HDL) cholesterol study 1.94 1.94 7.2.1.34 0 1.
low density lipoprotein (LDL) cholesterol study 1 0 2.44 2.44 7.2.1.35.
apolipoproteīn A1 1 study 2.81 0 2.81 7.2.1.36.
apolipoproteīn B 0 7.2.1.37 1 study 2.81 2.81.
soluble transferīn receptor study 1 0 6.43 6.43 7.2.1.38.
the cardiac troponin T (acute myocardial infarction Express) study 1 0 5.29 5.29 7.2.1.39.
Myoglobin 1 study 4.89 0 4.89 7.2.1.40.
insulin 1 study 4.57 0 4.57 7.2.1.41.
hyaluronic acid 1 study 9.80 0 9.80 7.2.1.42.
citokeratīn 18 (CK 18 neo-epitopes) study 1 0 6.51 6.51 7.2.1.43.
cytochrome c 0 7.2.1.44 1 study 9.84 9.84.
endotoxin core antibody (quantitative) study 1 0 7.69 7.69 7.2.1.45.
nitrates/nitrites (quantitative) study 5.19 5.19 7.2.1.46 1 0.
blood gas and environmental level (Ph) analysis 1 study 12.25 0 12.25 7.2.1.47.
serum (plasma) getting 1 study 0.39 0 0.39 7.2.2.
a study of likvor 7.2.2.1.
chlorides 1 study 1.40 0 1.40 7.2.2.2.
protein (quantitative) study 1 0 0.79 7.2.2.3 0.79.
glucose (quantitative) study 1 0 0.79 0.79 7.2.3.
punktāt investigation (protein (total)) 1 study 1.06 0 1.06 7.2.4.
imūnhematoloģij studies of 7.2.4.1.
determination of blood group ABO sis theme with planes method (double reaction) (A and B antigen detected by direct reaction of the horse, the anti-A and anti-B antibodies with the inverse reaction) 1 study 1.56 0 1.56 7.2.4.2.
rhesus factor (Rh (D)) signs with planes method (with two reagents) study 1 0 1.64 7.2.4.3 1.64.
rhesus factor (Rh (D)) features detection geltehnik (with one reagent) 0 1 study 1.78 1.78 7.2.4.4.
not full antieritrocitār antibody screening geltehnik (identification card information List/Coomb) 1 study 3.07 0 3.07 7.2.4.5.
determination of blood group ABO system with plaksn method (direct response) (A and B antigen with direct response) 1 study 0.86 0 0.86 7.2.4.6.
determination of blood group ABO system on Rh and geltehnik (A and B antigen detection by direct reaction, anti-A and anti-B antibodies with the inverse reaction, D Antigen) 1 study 3.74 0 3.74 7.2.4.7.
RH system phenotype (CcE) and the determination of the Kell geltehnik 1 0 5.68 5.68 7.2.4.8 study.
of the recipient and the donor's blood test in the individual compatibility Lab (ABO, Rh and other systems-geltehnik) 1 study 7.73 0 7.73 7.2.4.9.
a direct test of the anti-human globulin – (data) geltehnik (ID card List/Coomb) 1 study 1.97 0 1.97 7.2.5.
7.2.5.1 tests koaguloģij.
protrombīn index (INR) 1 study 1.62 0 1.62 7.2.5.2.
the activated partial tromboplastīn time (APTL) 1 study 1.79 0 1.79 7.2.5.3.
Fibrinogen 1 study 1.79 0 1.79 7.2.5.4.
study of Thrombin time 1 0 1.74 1.74 7.2.6.
urine investigation 7.2.6.1.
glukuronīd in urine 1 study 15.46 0 15.46 7.2.6.2.
protein (quantitative) study 1 0 0.79 0.79 7.2.6.3.
glucose (quantitative) study 1 0 0.79 0.79 7.2.6.4.
Alpha-1 amilāz study 2.35 0 2.35 7.2.6.5.
study of iron 1 0 1.58 1.58 7.2.6.6.
calcium 1 study 1.43 0 1.43 7.2.6.7.
urea (bun) study 1 0 1.43 1.43 7.2.6.8.
creatinine 1 study 1.43 0 1.43 7.2.6.9.
uric acid study 1.55 1.55 7.2.6.10 0 1.
determination of ethanol by enzymatic study 4.50 0 4.50 7.2.6.11 1.
drugs and their derivatives ekspresdiagnostik test (panel of four substances) 1 study 4.04 0 4.04 7.2.6.12.
drugs and their derivatives ekspresdiagnostik test (panel of eight substances) 1 study 6.57 0 6.57 7.2.7.
testing with dry chemistry analyser REFLOTRON 7.2.7.1.
determination of cholesterol by dry chemistry analyser REFLOTRON 1 study 1.78 0 1.78 7.2.7.2.
bilirubin determination by dry chemistry analyser REFLOTRON 1 study 1.78 0 1.78 7.2.7.3.

alanīnminotransferāz (AL) with dry chemistry analyser REFLOTRON 1 study 1.78 0 1.78 7.2.7.4.
aspartātaminotransferāz (S) with dry chemistry analyser REFLOTRON 1 study 1.78 0 1.78 7.2.7.5.
determination of triglycerides with dry chemistry analyser REFLOTRON 1 study 2.01 0 2.01 7.2.7.6.
pankreātisk determination of amylase by dry chemistry analyser 1 study IV 2.13 REFLOTRON 0 2.13 7.2.7.7.
determination of glucose by dry chemistry analyser REFLOTRON IV 1 study 0 7.2.7.8 1.90 1.90.
high density lipoproteins (HDL)-cholesterol determination by dry chemistry analyser REFLOTRON 1 study 2.12 0 2.12 7.2.7.9.
determination of urea (bun) with dry chemistry analyser 1 study IV 2.17 REFLOTRON 0 2.17 7.2.7.10.
determination of the concentration of creatinine with dry chemistry analyser REFLOTRON IV 1 0 2.09 2.09 7.2.7.11 study.
alpha-amylase activity detection with dry chemistry analyser REFLOTRON IV study 2.43 2.43 7.2.7.12 1 0.
determination of potassium with dry chemistry analyser REFLOTRON IV study 2.23 2.23 7.2.7.13 1 0.
gammaglutamīntransferāz (GG) activity detection with dry chemistry analyser REFLOTRON IV 1 study 2.02 0 2.02 7.3.
parasitological studies 7.3.1.
blood parasite (malaria, filariidoz) thick drops of 1 study 7.36 0 7.36 7.3.2.
Malaria blood smear pazmodij 1 the examination 8.27 0 8.27 7.3.3.
Blood of Plasmodi Ag (imūnhromatogrāfij) study 1 0 4.91 4.91 7.3.4.
analysis on the helminth (Kato) 1 study 1.58 0 1.58 7.3.5.
scrape from perianālaj folds to spalīš eggs 1 0 0.91 0.91 7.3.6 study.
investigation of enterobioz with adhesive tape method 1 study 0 1.21 1.21 7.3.7.
Pneumocyst a jiroveci (carini) Ag (IF)-Pneumocyst by jiroveci (carini) Antigen with indirect microscopy study of imūnfluorescenc 1 0 13.60 13.60 7.3.8.
Cryptosporidium Ag with faeces (ELISA), Cryptosporidium Antigen with imūnfermentatīv response 1 study 5.99 0 5.99 7.3.9.
lamblij and helminth determination of bile in preparation for native and sediment (three servings) 1 study 5.28 0 5.28 7.3.10.
protozoa and helminth cyst investigation with enrichment (concentration) method 4.13 0 1 study 4.13 7.3.11.
scabbers mite, dziedzerērc 1 the examination 5.28 0 5.28 7.3.12.
helmint and determination of their snippet 1 study 2.31 0 2.31 7.3.13.
intestinal protozoa parasite detection in preparation of the study natīv 1 0 2.79 7.3.14 2.79.
Anti-Toxocar-Canis IgG (ELISA) immunoglobulin G antibodies to the class of cērmj larvae of the dog study 1 0 4.26 4.26 7.3.15.
Anti IgG Trichinella spiralis (ELISA) immunoglobulin G antibodies against class Trichinella examination 0 1 4.26 4.26 7.3.16.
Echinococcus anti-IgG (ELISA) species-imūnglobulūn G class antibodies against ehinokok species (e. granulos, e. multilokular) 7.81 7.81 7.3.17 0 1 study.
-Echinococcus granulosus anti (IH)-HA antibody reaction to the unicameral ehinokok 8.80 0 8.80 1 study 7.3.18.
The compatible lambli (Ag faeces) (ELISA)-lamblij with imūnfermentatīv of Antigen reaction 1 study 5.99 0 7.3.19 5.99.
Anti-Entamoeb-hystolitic (IH)-HA antibody reaction to the hystolitic Entamoeb (the dysentery Amoeba) study 1 0 10.76 7.3.20 10.76.
Entamoeb hystolitic Ag in the faeces (ELISA) – the Amoeba dysentery Antigen with imūnfermentatīv response 1 study 0 6.61 7.3.21 6.61.
Anti-IgG (ELISA) of Taenia-immunoglobulin G antibodies against the class of the pig tapeworm larvae study 8.67 1 0 8.67 7.3.22.
Cysticercos by WB-cisticerk IgG immunoglobulin G antibody validation class with Western blot reaction in study 1 0 35.17 7.3.23 35.17.
Toxocar WB toksokar immunoglobulin G IgG-class antibody validation by Western blot reaction 31.72 0 31.72 7.3.24 1 study.
Trichinae Trichinella WB IgG-class antibody immunoglobulin G approval by Western blot reaction in study 1 0 35.17 7.3.25 35.17.
Echinoccoc-WB IgG immunoglobulin G ehinokok-class antibody validation by Western blot reaction 1 study 35.17 0 35.17 7.4.
veneroloģisk studies 7.4.1.
Chlamydia trachomatis Antigen (IFA) – Chlamydia trachomatis Antigen reactions of 1 with imūnfluorescenc study 4.51 0 4.51 7.4.2.
Chlamydia trachomatis Antigen (ELISA) – Chlamydia trachomatis Antigen with imūnfermentatīv response 1 study 8.89 0 8.89 7.4.3.
Trichomonas vaginal natīv peparāt in the determination of the study 1 1.21 0 1.21 7.4.4.
gynecological smears in 1 study 1.87 0 1.87 7.4.5.
syphilis diagnosis of Treponema pallidum haemagglutination-reaction (TPH) 1 study 1.67 0 1.67 7.4.6.
Syphilis diagnosis of Treponema pallidum haemagglutination-reaction (TPH) by titration 1 study 4.03 0 4.03 7.4.7.
Demonstration of Treponema pallidum by dark field microscopy in study 1 0 1.62 1.62 7.4.8.
syphilis Diagnostics-reagīn of precipitation (RPR) 1 study 1.43 0 1.43 7.4.9.
syphilis Diagnostics-reagīn of precipitation (RPR) with the titration study 1 0 4.07 4.07 7.4.10.
plating on Mycoplasma study 1 0 6.38 7.4.11 6.38.
on the culture study of ureaplazm 1 0 6.38 7.4.12 6.38.
plating on gonococcal (positive) study 1 0 10.14 10.14 7.4.13.
plating on gonococcal (negative) study 1 0 6.75 7.4.14 6.75.
reagīn precipitin reaction (RPR) 1 hour study 4.28 0 4.28 7.4.15.
sexually transmitted diseases (STDs) in the film the hour 1 study 3.75 0 3.75 7.4.16.
certificate to the syphilis study 3.05 1 0 3.05 7.4.17.
certificate-duplicate for syphilis to study 1 0 3.62 7.4.18 3.62.
Chlamydia trachomatis Antigen confirmatory test (ELISA) – Chlamydia trachomatis Antigen approval with imūnfermentatīv response 1 study 16.02 0 16.02 7.4.19.
Mycoplasma or ureplazm determination of sensitivity to antibiotics 1 study 5.61 0 5.61 7.5.
hepatitis diagnostic 7.5.1.
Anti-HAV: antibody (ELISA) against hepatitis A virus through a study of the reaction of 1 imūnfermentatīv 5.50 0 5.50 7.5.2.

Anti-HAV IgM (ELISA) immunoglobulin M antibodies against hepatitis a in class (A) virus detection with imūnfermentatīv response 1 study 0 6.04 6.04 7.5.3.
HAVE Ag (ELISA)-hepatitis A virus Antigen detection with imūnfermentatīv response 1 study 6.92 0 6.92 7.5.4.
HBS Ag (ELISA)-hepatitis B virus surface antigen with imūnfermentatīv response 1 study 3.43 0 3.43 7.5.5.
HBsAg Confirmatory (ELISA)-hepatitis B virus surface antigen positive test 1 study 8.28 0 8.28 7.5.6.
Anti-HBS quantitative (ELISA) – antibody against hepatitis B virus identification with imūnfermentatīv response 1 study 7.27 0 7.27 7.5.7.
Anti-HBc antibody (ELISA) – against the hepatitis B virus core Antigen with imūnfermentatīv response 1 study 0 5.81 5.81 7.5.8.
Anti-HBc IgM (ELISA) immunoglobulin M antibody class against hepatitis B virus core Antigen with imūnfermentatīv response 1 study 0 6.47 6.47 7.5.9.
HBE Ag (ELISA)-hepatitis B virus E Antigen with imūnfermentatīv reaction study 7.52 7.52 7.5.10 0 1.
Anti-HBE antibody (ELISA) – against the hepatitis B virus E Antigen with imūnfermentatīv response 1 study 0 7.52 7.52 7.5.11.
Anti-HCV (ELISA) – antibody against hepatitis C virus detection with imūnfermentatīv response 1 study 6.80 0 6.80 7.5.12.
Anti-HCV positive test (WB) – antibody against hepatitis C virus confirmation with Western blot reaction in study 1 0 44.57 44.57 7.5.13.
HCV RNA (PCR) – hepatitis C virus ribonukleīnskāb detection with polymerase chain reaction study 1 0 51.30 7.5.14 51.30.
HD Ag (ELISA)-Hepatitis delta virus Antigen detection with imūnfermentatīv response 1 5.95 0 5.95 7.5.15 study.
Anti-HD (ELISA) immunoglobulin IgM-class antibodies against M Hepatitis delta virus detection with imūnfermentatīv response 1 study 5.95 0 5.95 7.5.16.
AFP (ELISA)-alpha-fetoproteīn detection with imūnfermentatīv response 1 study 4.69 0 4.69 7.5.17.
HBS Ag Other (ELISA)-ta B virus surface in hepat Antigen detection with imūnfermentatīv quick response within two hours of study 1 0 9.32 9.32 7.5.18.
Anti-HAV IgM, the Other (ELISA) immunoglobulin M antibody against hepatitis class A quick detection of the virus with imūnfermentatīv reaction within two hours of study 1 0 12.37 7.5.19 12.37.
Anti-HBc (ELISA) – Other antibodies against hepatitis B virus core Antigen within two hours of study 1 0 12.19 12.19 7.5.20.
Anti-HCV (ELISA) – Other antibodies against hepatitis C virus the quick reaction of imūnfermentatīv with two hours of study 1 0 13.02 13.02 7.5.21.
HBS Ag certificate (ELISA)-hepatitis B virus surface antigen with imūnfermentatīv response 1 study 5.18 0 7.5.22 5.18.
HBS Ag certificate (ELISA)-hepatitis B virus surface antigen with imūnfermentatīv reaction within two hours of study 1 0 8.28 8.28 7.5.23.
Anti-HD (ELISA) immunoglobulin IgG-class antibodies against G Hepatitis delta virus detection with imūnfermentatīv response 1 0 7.5.24 5.95 5.95 study.
HCV RNA load (PCR) – hepatitis C virus ribonukleīnskāb's determination with polymerase chain reaction study 1 105.34 7.5.25 105.34.
HCV genotipēšan (molecular hybridization)-hepatitis C virus genotype detection 1 147.89 147.89 7.5.26 study.
HBV DNA (PCR) load-hepatitis B virus dezoksiribonukleinskāb determination of polymerase chain reaction with 1 88.83 0 88.83 7.5.27 study.
Anti-HEV IgM (ELISA) immunoglobulin M antibody against hepatitis class E virus detection with imūnfermentatīv response 1 0 7.5.28 12.87 12.87 study.
Anti-HEV IgG (ELISA) immunoglobulin G antibody against hepatitis class E virus detection with imūnfermentatīv response 1 study 9.71 0 9.71 7.6.
HIV/AIDS Diagnostics 7.6.1.
Anti-HIV 1/2 antibody against the quick method — human immunodeficiency virus 1 and/or 2 with quick determination method study 1 0 4.22 4.22 7.6.2.
Anti-HIV 1/2 to the certificate (ELISA) – antibody against human immunodeficiency virus 1 and/or 2 with imūnfermentatīv response 1 study 10.01 0 10.01 7.6.3.
Anti-HIV 1/2 with certificate and duplicate (ELISA) – antibody against human immunodeficiency virus 1 and/or 2 with imūnfermentatīv response 1 study 10.70 0 10.70 7.6.4.
Anti-HIV 1/2 with the quick method, and a certificate – antibody against human immunodeficiency virus 1 and/or 2 with quick determination method study 1 0 11.73 11.73 7.6.5.
Anti-HIV 1/2 with the quick method, the certificates and duplicates – antibody against human immunodeficiency virus 1 and/or 2 with quick determination method study 1 0 12.42 12.42 7.6.6.
Anti-HIV 1/2 antibody (ELISA) against human immunodeficiency virus 1 and/or 2 with imūnfermentatīv response 1 study 0 4.53 4.53 7.6.7.
HIV load (HIV RNA Kwan)-HIV RNA quantification with polymerase chain reaction in study 1 109.50 109.50 7.6.8.
Anti-HIV 1/2 Ag (ELISA) and HIV-antibody against at the human immunodeficiency virus 1 and/or 2 and human immunodeficiency virus Antigen detection with imūnfermentatīv response 1 study 0 4.53 4.53 7.6.9.
Anti-HIV-1 and/or 2 the confirmatory test for antibodies against the WB-human immunodeficiency virus 1 and/or 2 approval by Western blot reaction in study 1 0 31.36 31.36 7.6.10.
Ag (ELISA)-HIV human immunodeficiency virus Antigen with imūnfermentatīv response 1 study 0 15.62 15.62 7.6.11.
HIV Ag confirmatory (ELISA with neutralization), human immunodeficiency virus Antigen approval with imūnfermentatīv reaction with a 1 40.23 0 itrālizācij study 40.23 7.6.12.
HIV (human immunodeficiency virus) genotipēšan resistance detection (sequencing) study 441.62 441.62 1 7.7.
immunological studies 7.7.1.
imūnstatus-determination of lymphocyte imunofenotip quantitative (absolute number,%) (CD3/CD4/CD8 CD3, CD16 + CD3 CD56 CD19, HLA-DR, HLA-DR/CD3), flow citometrij study 1 0 29.92 29.92 7.7.2.
T-lymphocytes in the imunofenotip determination (absolute number,%) (CD3/CD 4, CD3/CD8), flow citometrij study 1 0 24.54 24.54 7.7.3.
imūnregulējoš cell: CD195 (CCR5), flow citometrij study 1 0 8.91 7.7.4 8.91.

the human Antigen B count tipēšan by molecular hybridization (HLA B-human leucocyt antigen of B) 1 107.33 107.33 7.8 study.
Herpes group virus infection Diagnostics 7.8.1.
Anti-CMV IgG quantitative, (ELISA) immunoglobulin G antibody against citomegalovīrus class through the imūnfermentatīv reaction 1 study 6.70 0 6.70 7.8.2.
Anti-CMV IgM (ELISA) immunoglobulin M antibodies against citomegalovīrus of class through the imūnfermentatīv reaction study 1 0 5.90 5.90 7.8.3.
Anti-HSV IgM (ELISA) immunoglobulin M antibody class against herpes simplex virus type 1 and 2 with imūnfermentatīv response 1 study 6.10 0 6.10 7.8.4.
HSV1/2 Ag IF – herpes simplex virus 1 and 2 types of Antigen detection by microscopy study of imūnfluorescenc 1 0 7.19 7.19 7.8.5.
Anti-IgG quantitative HSV1/2 (ELISA) immunoglobulin G class antibodies against herpes simplex type 1 and 2 a quantification with imūnfermentatīv response 1 study 0 6.15 7.8.6 6.15.
Anti-VZV (HZV) IgM (ELISA) immunoglobulin M antibodies against Varicell of the class (or herpes zoster) zoster virus detection with imūnfermentatīv response 1 study 0 7.45 7.45 7.8.7.
Anti-VZV (HZV) IgG quantitative (ELISA) immunoglobulin G antibody-class against the Varicell (or herpes zoster) zoster virus identification with imūnfermentatīv response 1 study 0 8.82 7.8.8 8.82.
Anti-CMV IgG aviditāt (ELISA) immunoglobulin G antibodies against citomegalovīrus of class aviditāt with imūnfermentatīv determination of reaction 1 study 8.79 0 8.79 7.8.9.
CMV DNA quantitative (PCR-RL) – citomegolovīrus's (CMV DNA) DNA quantification with PCR in real time (RT-PCR) 1 study 44.63 0 44.63 7.8.10.
CMV DNA (PCR) – quality of DNA citomegalovīrus (CMV DNA) identification with polymerase chain reaction (PCR) 1 study 15.88 0 15.88 7.8.11.
Anti-EBV EA (ELISA) immunoglobulin IgM-class antibodies against M Epstein-Barr virus early Antigen detection with imūnfermentatīv response 1 study 5.18 0 7.8.12 5.18.
Anti-EBV EA IgG quantitative (ELISA) immunoglobulin G antibody against Epstein in class-Barr virus early Antigen determination with imūnfermentatīv response 1 study 5.18 0 7.8.13 5.18.
Anti-VCA IgM EBV (ELISA) immunoglobulin M antibody against Epstein in class-Barr viral antigen detection by a skin reaction imūnfermentatīv study 7.8.14 1 0 4.95 4.95.
Anti-VCA IgG EBV quantitatively (ELISA) immunoglobulin G antibody against Epstein in class-Barr virus Antigen determination shell with imūnfermentatīv response 1 study 5.72 0 5.72 7.8.15.
Anti-EBV IgG quantitative EBN (ELISA) immunoglobulin G antibody against Epstein in class-Barr virus nuclear antigen determination with imūnfermentatīv response 1 study 6.46 0 6.46 7.8.16.
Anti-EBV IgM, WB-immunoglobulin M antibody against Epstein in class-Barra viral validation by Western blot reaction 1 study 31.67 0 31.67 7.8.17.
Anti-EBV IgG immunoglobulin G, WB-class antibodies against Epstein-Barr virus confirmation with Western blot reaction 1 study 31.67 0 31.67 7.8.18.
EBV DNA quantitative (PCR-RL), Epstein-Barr virus (EBV) DNA (DNA) identification by PCR in real time (RT-PCR) 1 study 44.63 0 44.63 7.8.19.
EBV DNA (PCR) quality-Epstein-Barr virus (EBV) DNA (DNA) detection quality with polymerase chain rekcij (PCR) 1 study 15.88 0 15.88 7.8.20.
HSV 1/2 DNA (quantitative (PCR-RL)-Herpes simplex type 1 and 2 a quantitative determination of DNA by polymerase chain reaction real time study 7.8.21 1 0 44.63 44.63.
HSV1/2 DNA (PCR) quality – herpes simplex 1 and 2, the determination of the subtip DNA (DNA) quality of polymerase chain reaction (PCR) 1 study 15.88 0 15.88 7.8.22.
herpes virus isolation and tipēšan (tissue culture) study 7.8.23 1 0 21.00 21.00.
immunoglobulin M antibodies against T.O.R.C.H. class group infections (toxoplasmosis, rubella, herpes infections and citomegalovīrus) by Western blot reaction 1 study 31.67 0 31.67 7.8.24.
VZV (HZV) DNA quantitative (PCR-RL) – Varicell's (or herpes zoster) zoster virus DNA quantitative detection by polymerase chain reaction (PCR) real time study 1st 0 44.63 44.63 7.8.25.
VZV (HZV) DNA (PCR) – quality of Varicell zoster (zoster or Herpes) virus detection dezribonukleīnskāb by polymerase chain reaction (PCR) 1 study 15.88 0 15.88 7.9.
respiratory viral infection Diagnostics 7.9.1.
influenza A virus Antigen with imūnfluorescenc in study 1 0 7.94 7.94 7.9.2.
influenza B virus Antigen with imūnfluorescenc in study 1 0 7.94 7.94 7.9.3.
Influenza virus a/B ribonukleīnskāb (RN) with high quality with polymerase chain reaction (PCR), 27.60 0, 27.60 7.9.4 1 study.
Influenza virus a/B ribonukleīnskāb (RNA) of high quality with the polymerase chain reaction (PCR-RL) real time study 1 0 44.63 44.63 7.9.5.
A flu virus subtip through polymerase chain reaction (PCR) of high quality, if A flu virus RNA (RNA), 27.60 is positive 1 study 0 27.60 7.9.6.
A flu virus subtip through polymerase chain reaction (PCR-RL) in real time, if A flu virus RNA (RNA) is the study of positive 1 0 44.63 44.63 7.9.7.
paragrip viral antigen with imūnfluorescenc in study 1 0 7.94 7.94 7.9.8.
paragrip virus tipēšan with imūnfluorescenc 1 the examination 13.46 0 13.46 7.9.9.
adenovīrus the Antigen with imūnfluorescenc in study 1 0 7.94 7.9.10 7.94.
adenovīrus isolation from clinical material 1 study 22.86 0 22.68 7.9.11.
complement fixation detection of the adenovīrus study 7.9.12 1 0 7.53 7.53.
respirators in virus Antigen sincitiāl (RSV, Ag) detection with imūnfluorescenc 1 the examination 0 7.94 7.94 7.9.13.
Anti-RSV IgM (ELISA) immunoglobulin M antibodies against respiratory class in virus detection with sincitiāl imūnfermentatīv response 1 0 6.24 6.24 7.9.14 study.

haemagglutination (HA) inhibition with one Antigen (influenza A/H1N1, A/H3N2, B, paragrip, types I, II and III) study 1 0 6.76 6.76 7.9.15.
influenza virus isolation in tissue culture and tipēšan study 1 0 21.00 21.00 7.10.
acute viral gastroenteritis diagnostic 7.10.1.
adenovīrus Ag (ELISA)-adenovīrus with imūnfermentatīv the Antigen response 1 study 6.92 0 6.92 7.10.2.
rotavirus Ag (ELISA)-rotavirus Antigen with imūnfermentatīv response 1 study 6.92 0 6.92 7.10.3.
astrovīrus Ag (ELISA)-astrovīrus with imūnfermentatīv the Antigen response 1 study 6.92 0 6.92 7.10.4.
programme identifying norovirus Ag (ELISA) – a programme identifying norovirus Antigen with imūnfermentatīv response 1 study 9.17 0 9.17 7.10.5.
the ribonukleīnskāb programme identifying norovirus (RNA) determination qualitative PCR (PCR) 1 study 15.88 0 15.88 7.11.
7.11.1 involved infections Diagnostics.
the distribution of tipēšan involved and study 1 0 30.74 30.74 7.11.2.
complement fixation detection of the study involved 1 0 7.53 7.53 7.11.3.
involved in RNA (PCR-RL) quantitative-of the determination involved ribonukleīnskāb by polymerase chain reaction real time study 1st 44.63 0 44.63 7.11.4.
involved in RNA (PCR)-the quality of the identification of the involved ribonukleīnskāb by polymerase chain reaction in study 1 0 15.88 15.88 7.11.5.
the distribution of involved tissue culture study 22.68 7.11.6 22.68 0 1.
neutralization reaction tissue culture with poliovīrus type 1 study 8.37 0 8.37 7.12.
tick-borne infections Diagnostics 7.12.1.
Anti-TBE IgM likvor (ELISA) immunoglobulin M antibodies against ticks class encephalitis virus detection with imūnfermentatīv response 1 study 0 5.97 5.97 7.12.2.
Anti Borrelia burgdorferi IgG immunoglobulin G (WB)-class antibodies against Borrelia burgdorferi approval by Western blot reaction 1 study 24.02 0 24.02 7.12.3.
Anti-TBE IgM (ELISA) immunoglobulin M antibodies against ticks class encephalitis virus detection with imūnfermentatīv response 1 study 6.90 0 6.90 7.12.4.
Anti-TBE-IgG (ELISA) immunoglobulin G antibody against ticks class encephalitis virus detection with imūnfermentatīv reaction study 7.71 1 0 7.12.5 7.71.
Anti-Ehrlichi (Anaplasm) with imūnfluorescenc in study 1 IgG 11.58 0 11.58 7.12.6.
Anti-Ehrlichi (Anaplasm) imūnfluorescenc 1 the examination with IgM 11.58 0 11.58 7.12.7.
Anti Borrelia burgdorferi IgM (ELISA) immunoglobulin M antibody class against Borrelia burgdorferi determination by imūnfermentatīv response 1 study 6.80 0 6.80 7.12.8.
Anti Borrelia burgdorferi IgG (quantitative) (ELISA) immunoglobulin G class antibodies against Borrelia burgdorferi determination by imūnfermentatīv response 1 0 7.12.9 7.19 7.19 study.
Anti Borrelia burgdorferi IgM (WB) – immunoglobulin M antibody class against Borrelia burgdorferi approval by Western blot reaction 1 24.02 0 24.02 7.12.10 study.
Borrelia DNA (PCR-RL) – Borrelia dezoksiribonukleīn acid detection with polymerase chain reaction real time study 1st 49.57 0 49.57 7.13.
rare and imported infections the serological and molecular biological diagnostic 7.13.1.
Anti-virus IgM Hunt (ELISA) immunoglobulin M antibodies against the hunt class virus detection with imūnfermentatīv response 1 study 15.56 0 15.56 7.13.2.
Anti-Hunt (ELISA) immunoglobulin IgG-class antibodies against G Hunt virus detection with imūnfermentatīv response 1 study 16.99 0 16.99 7.13.3.
Anti-IgM burett of Coxiell (Q fever, ELISA) immunoglobulin M antibodies against Coxiell of the class of antigens by burnett imūnfermentatīv response 1 study 16.32 0 16.32 7.13.4.
Anti-IgG burnett of Coxiell (Q fever, ELISA) immunoglobulin G antibody against the class Coxiell Antigen detection by burnett imūnfermentatīv study of reaction 1 0 16.99 7.13.5 16.99.
The pneumophil's of anti-IgM Legionell (ELISA) immunoglobulin M antibodies against class a pneumophil discovery with Legionell imūnfermentatīv response 1 study 9.44 0 9.44 7.13.6.
Anti-pneumophil of IgG Legionell (ELISA) immunoglobulin G antibody against the class of the pneumophil discovery with Legionell imūnfermentatīv response 1 study 9.44 0 9.44 7.13.7.
Anti-Deng-IgM (ELISA) immunoglobulin M antibody-class against the virus by Deng imūnfermentatīv study of reaction 1 0 12.45 12.45 7.13.8.
Anti-Deng-IgG (ELISA) immunoglobulin G antibody-class against the virus by Deng imūnfermentatīv study of reaction 1 0 12.45 12.45 7.13.9.
Deng is RNA (PCR-RL)-Deng-ribonukleīnskāb detection of virus by PCR in real time study 1st 63.10 0 63.10 7.13.10.
Anti-Puumal (ELISA) of IgM-class antibodies of immunoglobulin M against Puumal virus detection to the imūnfermentatīv study of the reaction of 1 0 16.10 16.10 7.13.11.
Anti-West-Nile (ELISA) immunoglobulin IgM-class antibodies against M West-Nile virus detection with imūnfermentatīv response 1 0 12.45 12.45 7.13.12 study.
Anti-West-Nile (ELISA) immunoglobulin IgG-class antibodies against a G West-Nile virus detection with imūnfermentatīv response 1 0 12.45 12.45 7.13.13 study.
West-Nile-RNA (PCR RL) West-Nile virus detection ribonukleīnskāb by polymerase chain reaction real time study 7.13.14 1 0 63.03 63.03.
Anti-SARS-CoV IgM (ELISA) immunoglobulin M antibodies against SARS class CoV by imūnfermentatīv response 1 0 11.73 11.73 7.13.15 study.
Anti-SARS-CoV IgG (ELISA) immunoglobulin G antibodies against SARS class CoV by imūnfermentatīv response 1 0 11.73 11.73 7.13.16 study.
SARS CoV (PCR RL) – SARS CoV ribonukleīnskāb detection with polymerase chain reaction real time study 63.03 63.03 7.14 0 1.
various infectious disease serological and molecular biological diagnostic 7.14.1.
Anti-rubella IgM (ELISA) immunoglobulin M antibodies against rubella class virus detection to the imūnfermentatīv study of the reaction of 1 0 8.82 7.14.2 8.82.
Anti-rubella quantitative IgG (ELISA) immunoglobulin G antibodies against rubella class viral quantification with imūnfermentatīv response 1 study 7.69 0 7.69 7.14.3.

Anti-Mycoplasma pneumoniae IgM (ELISA) immunoglobulin M antibodies against Mycoplasma class pneumoniae with imūnfermentatīv response 1 study 7.25 0 7.14.4 7.25.
Anti-Mycoplasma pneumoniae IgG (ELISA) immunoglobulin G antibody against Mycoplasma class pneumoniae with imūnfermentatīv response 1 study 7.48 0 7.48 7.14.5.
Anti-Chlamydia pneumoniae IgM (ELISA) immunoglobulin M antibodies against Chlamydia class pneumoniae with imūnfermentatīv response 1 study 7.82 0 7.82 7.14.6.
Anti-Chlamydia pneumoniae IgG quantitative (ELISA) immunoglobulin G antibody against Chlamydia class pneumoniae with imūnfermentatīv response 1 study 7.82 0 7.82 7.14.7.
Anti-Toxoplazm (ELISA) of IgM-class antibodies of immunoglobulin M determination of the imūnfermentatīv against Toxoplazm response 1 study 6.51 0 6.51 7.14.8.
Anti-Toxoplazm IgG (quantitative) (ELISA) immunoglobulin G antibodies against Toxoplazm of class identification with imūnfermentatīv response 1 study 5.36 0 5.36 7.14.9.
Anti-Toxoplazm IGA (ELISA) immunoglobulin A antibodies against Toxoplazm of class determination with imūnfermentatīv manmad reaction 1 study 4.98 0 4.98 7.14.10.
Anti-IgG aviditāt, Toxoplazm (ELISA) immunoglobulin G antibody against Toxoplazm classes in the aviditāt detection with manmad imūnfermentatīv study of reaction 1 0 8.79 8.79 7.14.11.
Anti-Rubeol (ELISA) of IgM-class antibodies of immunoglobulin M against measles virus detection with imūnfermentatīv response 1 0 9.25 9.25 7.14.12 study.
Anti-Rubeol IgG quantitative (ELISA) immunoglobulin G antibody against measles class viral quantification with imūnfermentatīv response 1 0 9.79 9.79 7.14.13 study.
measles (Rubeol) virus isolation in tissue culture study 21.00 21.00 7.14.14 1 0.
Anti-parvovīrus-B19 IgM (ELISA) immunoglobulin M antibodies against parvovīrus of the class with imūnfermentatīv B19 reaction 1 study 7.60 0 7.60 7.14.15.
Parvovīrus B19 IgG Anti-a quantitative (ELISA) immunoglobulin G antibodies against parvovīrus of class determination with B19 imūnfermentatīv response 1 study 7.92 0 7.92 7.14.16.
papilloma virus (low and high risk of oncogenes) determination by hybridisation 1 40.78 0 40.78 7.14.17 study.
Anti-Diphteri (ELISA) of Toxoid IgG immunoglobulin G antibody-class against the Toxoid imūnfermentatīv Diphteri by reaction 1 study 7.07 0 7.14.18 7.07.
Anti-IgM Mump (ELISA) immunoglobulin M antibodies against mumps class virus with imūnfermentatīv response 1 8.42 0 8.42 7.14.19 of the study.
Anti-IgG by Mump (ELISA) immunoglobulin G antibody-class against mumps virus with imūnfermentatīv response 1 study 7.83 0 7.83 7.15.
bacteriological studies 7.15.1.
bacteriological analysis 7.15.1.1.
blood – with the conventional method (negative) study 1 0 10.06 10.06 7.15.1.2.
blood-with automatic system (negative) study 1 0 10.78 10.78 7.15.1.3.
blood – with the conventional method (positive) study 1 0 14.62 14.62 7.15.1.4.
blood-with automatic system (positive) study 1 0 15.85 15.85 7.15.1.5.
the lumbar punktāt (negative) study 7.15.1.6 1 0 9.17 9.17.
the lumbar punktāt, without isseri the serological detection of n. meningitidis tipēšan (positive) 1 study 19.04 0 19.04 7.15.1.7.
the punktāt – with a lumbar isseri meningitidis serological tipēšan of (positive) 1 study 17.40 0 17.40 7.15.1.8.
plating of the neck – Not the isseri meningitidis (negative) 1 study 5.08 0 5.08 7.15.1.9.
plating of the neck – without isseri the serological detection of n. meningitidis tipēšan (positive) 1 study 10.94 0 7.15.1.10 10.94.
plating of the neck – with the serological detection of n. meningitidis tipēšan isseri (positive) 1 study 16.02 0 16.02 7.15.1.11.
urine (negative) 1-7.23 0 7.23 7.15.1.12 study.
urine (positive) study 1 0 13.55 13.55 7.15.1.13.
bile (negative) study 1 0 7.35 7.35 7.15.1.14.
bile (positive) study 1 0 14.17 14.17 7.15.1.15.
pus, discharge, punktāt, rinse waters (negative) study 1 0 10.43 10.43 7.15.1.16.
pus, discharge, punktāt, rinse waters (positive) study 1 0 14.93 14.93 7.15.1.17.
sputum (negative) study 1 0 5.83 5.83 7.15.1.18.
sputum examination (positive) 1 0 15.87 15.87 7.15.1.19.
plating of the neck – beta haemolytic streptococci (negative) study 1 0 8.23 8.23 7.15.1.20.
plating of the neck – beta haemolytic streptococci (positive) study 1 0 10.37 10.37 7.15.1.21.
plating on different materials – Staphylococcus aureus (negative) study 1 0 4.31 4.31 7.15.1.22.
plating on different materials – Staphylococcus aureus (positive) study 1 0 5.27 5.27 7.15.1.23.
the culture of the throat and nose, Corynebacterium diphtheriae the – (negative) 1 study 9.35 0 9.35 7.15.1.24.
the culture of the throat and nose, Corynebacterium diphtheriae-(positive) study 1 0 13.85 13.85 7.15.1.25.
the culture of the throat and nose, Corynebacterium diphtheriae, the unified system (positive) study 1 0 7.15.1.26 14.21 14.21.
stools – Shigella, salmonella (negative) study 1 0 7.15.1.27 6.11 6.11.
stools – Shigella, salmonella, with the unified system (positive identification to serotype) study 1 0 11.74 11.74 7.15.1.28.
-selection of stools Escherichia (negative) study 1 0 6.96 6.96 7.15.1.29.
-selection of stools Escherichia (positive) study 1 0 9.26 9.26 7.15.1.30.
stools-Escherichia coli 0157 (negative) study 1 0 5.88 5.88 7.15.1.31.
stools-Escherichia coli 0157 (positive) study 1 0 11.44 11.44 7.15.1.32.
different materials-enterobacteriaceae (negative) study 1 0 6.91 6.91 7.15.1.33.
different materials-enterobacteriaceae (positive) study 1 0 8.60 8.60 7.15.1.34.
materials (faeces, urine from the neck) – the genus Yersinia bacteria (negative) study 1 0 5.97 5.97 7.15.1.35.
materials (faeces, urine from the neck)-Yersinia bacteria of the genus with the conventional method (positive) study 1 0 14.66 14.66 7.15.1.36.
materials (faeces, urine from the neck)-Yersinia genus bacteria – identification with a unified system (positive) study 1 0 9.56 9.56 7.15.1.37.

plating of different materials to the genus Candida fungi (negative) study 1 0 3.86 3.86 7.15.1.38.
plating from the neck to the genus Candida fungi (positive) 0 7.15.1.39 1 study 7.07 7.07.
materials (faeces, urine, the lumbar punktāt, blood)-bacteria of the genus Campylobacter (negative) study 1 0 6.67 6.67 7.15.1.40.
materials (faeces, urine, the lumbar punktāt, blood), Campylobacter bacteria in the genus with species identification of up-with the unified system (positive) study 1 0 21.28 21.28 7.15.1.41.
anaerobic micro-organisms (negative) 1 study 11.32 0 11.32 7.15.1.42.
anaerobic micro-organisms: the identification with the unified system (positive) study 1 0 20.72 20.72 7.15.1.43.
Vibrio cholerae stools – (negative) study 1 0 6.24 6.24 7.15.1.44.
Vibrio cholerae stools – (positive) study 1 0 8.28 8.28 7.15.1.45.
the antibiotic sensitivity detection of micro-organisms with the unified system study 1 0 7.91 7.91 7.15.1.46.
Botulism-bioprov 1 the examination 0 17.03 17.03 7.15.1.47.
plating on Clostridium botulinum (negative) 1 study 11.32 0 11.32 7.15.1.48.
plating on Clostridium botulinum (positive) study 1 0 20.72 20.72 7.15.1.49.
distributed micro-organisms antibiotic sensitivity determination by disk method 1 study 6.53 0 6.53 7.15.1.50.
the culture of the different materials – MRSA – Methicillin S. aureus (negative) study 1 0 5.45 5.45 7.15.1.51.
plating of various types – MRSA in materia-meticilīnrezisten make s. aureus (positive) 0 7.15.1.52 1 study 8.17 8.17.
in s. aureus Methicillin Mec Gene Discovery (MRSA) polymerase chain reaction (PCR-RL) real time study 1st 44.63 0 44.63 7.15.1.53.
stools – Shigella, salmonella, with unified method (positive identification to serotype) study 1 0 10.21 10.21 7.15.1.54.
plating of different materials on the Candida fungi of the genus with the unified system (positive, negative) 1 study 8.63 0 8.63 7.15.2.
7.15.2.1 serological analysis.
agglutination reaction of bacterial infections (such as whooping cough, typhoid fever, tularemia, brucellosis) study 1 0 3.14 7.15.2.2 3.14.
Aspergillus Antigen with lateksaglutinācij (LA) 1 7.14 0 7.14 7.15.2.3 study.
Candida Antigen with lateksaglutinācij (LA) 1 7.14 0 7.14 7.15.2.4 study.
haemagglutination reaction bacterial infection (salmonellosis, shigellosis, yersiniosis, pseidotuberkuloz) 1 study 4.40 0 4.40 7.15.2.5.
Cryptococc of Antigen with lateksaglutinācij (LA) 1 study 0 10.43 10.43 7.15.2.6.
Clostridium difficile toxin A discovery 1 study 8.63 0 8.63 7.15.2.7.
Group a beta haemolytic Streptococcus in the quick test 1 study 2.97 0 2.97 7.15.2.8.
microscopic diagnosis of leprosy study 1 0 1.84 1.84 7.16.
environmental studies 7.16.1 objects.
HAVE Ag (ELISA)-(A) vīrushep the surrounding Antigen with imūnfermentatīv reaction (health studies) study 1 0 8.17 8.17 7.16.2.
involved and the distribution of adenovīrus (sanitary examination) 1 study 30.74 0 30.74 7.16.3.
tick-borne encephalitis (TBE) virus Antigen (ELISA) imūnfermentatīv reaction to mite 1 study 10.47 0 10.47 7.16.4.
the washings of environmental objects (positive), the study passage 1 0 6.34 7.16.5 6.34.
the washings of environmental objects (negative)-passage 1 study 4.16 0 4.16 7.17.
laboratory studies of other medical institutions study of price 1 League 0 League price of 7.18.
morphological study of liver bioptāt-light microscopy examination 0 1 19.55 19.55 8.
Image diagnostic 8.1.
ultrasonoskopisk investigation in 8.1.1.
abdominal sonogrāfij (not including the pelvic organs, with vascular measurement) study 1 0 9.70 9.70 8.1.2.
one of the repeated sonogrāfij of organs (one study) 5.70 5.70 8.1.3 0 1 study.
kidney, urinary tract, prostate sonogrāfij study 9.10 1 0 9.10 8.1.4.
a woman's pelvic organs examination 1 sonogrāfij 0 9.10 8.1.5 9.10.
mammary sonogrāfij study 1 0 9.10 8.1.6 9.10.
Ultrasonic control made puncture 1 study 23.30 0 23.30 8.1.7.
thyroid, muscle, tendons, joints and other superficial structures ultrasound placed 1 8.80 0 8.80 8.1.8 study.
rectal and intravagināl sonogrāfij in study 1 0 8.00 8.00 8.2.
x-ray investigation 8.2.1.
the thoracic cavity organs 1 study screened 5.10 0 5.10 8.2.2.
the thoracic cavity organs review company 1 study 5.10 0 5.10 8.2.3.
the thoracic cavity organs company in two planes study 4.00 4.00 1 0 8.2.4.
the thoracic cavity organs one extra company, including esophageal kontrastēšan 1 the examination 0 6.25 6.25 8.2.5.
other institutions of the radiograph evaluation one study 1 study 2.00 2.00 0 8.2.6.
abdominal examination 0 1 screened 4.55 4.55 8.2.7.
abdominal company 1 0 5.70 5.70 8.2.8 study.
Esophageal kontrastizmeklēšan (and Gramma screened) 1 study 13.70 0 13.70 8.2.9.
esophageal, gastric and duodenal kontrastizmeklēšan of study 1 0 21.65 21.65 8.2.10.
esophagus, stomach and duodenum to the rectum, small intestine kontrastizmeklēšan the investigation to study the ileocekāl area 1 0 24.00 8.2.11 24.00.
colon Arcade 1 study 19.60 0 19.60 8.2.12.
irigoskopij 1 the examination 36.40 0 36.40 8.2.13.
intravenous urogrāfij study 1 0 21.20 21.20 8.2.14.
one tooth company 1 study 3.40 0 3.40 8.2.15.
mandibular x-ray images (biplane) 5.70 5.70 8.2.16 0 1 study.
skull x-ray images two planes 1 0 8.00 8.00 8.2.17 study.
skull x-ray each part 1 study 4.50 0 4.50 8.2.18.
Sinus one radiograph 1 study 4.50 0 4.50 8.2.19.
the chest bone or part of a single radiograph 1 study 6.00 0 8.2.20 6.00.
limb or part of a single radiograph 1 study 6.00 0 6.00 8.2.21.
the shoulder bar or pelvic radiograph of part 1 study 6.00 0 6.00 8.2.22.
pelvic bone radiograph examination report 1 0 6.25 8.2.23 6.25.
one part of the spine radiograph (biplane)

1 study 10.25 0 10.25 8.2.24.
larynx, throat, trachea, oesophagus, one of the top 1 study 5.35 0 5.35 8.2.25.
digital print on 24 x 30 cm movie 1 study 1.00 0 8.2.26 1.00.
digital print 35 x 43 cm to 1 study the movie 2.00 2.00 0 8.2.27.
Digital x-ray recording disk 1 0 1.50 1.50 8.2.28 study.
liver puncture Biopsy study 33.70 33.70 9 0 1.
Functional diagnostics 9.1.
ezofagoskopij 1 the examination 10.60 0 10.60 9.2.
gastroskopij or duodenoskopij 1 the examination 27.35 0 27.35 9.3.
rektoskopij 1 the examination 7.40 0 7.40 9.4.
colon examination to lean angle 1 study 29.60 0 29.60 9.5.
total colon examination 1 study 46.70 0 46.70 9.6.
duodenāl probing study 9.15 0 9.15 9.7 1.
cleansing enema study 4.30 4.30 9.8 1 0.
Pulse frequency and arterial pressure in study 1 0.30 0 0.30 9.9.
electrocardiography with 12 Nova game (note) 1 study 1.95 0 1.95 9.10.
electrocardiography with 12 counties for you (description) 1 study 2.75 0 2.75 9.11.
with fewer than 12 lead electrocardiography (notes) 1 study 0.80 0 0.80 9.12.
with fewer than 12 lead electrocardiography (description) 1 study 1.15 0 1.15 9.13.
During description (compared to at least five the ECG) 1 study 3.75 0 3.75 9.14.
electrocardiography (recorded with a portable machine on site) 4.50 0 9-1 study 4.50.
ehokardiogrāfij M and B mode real-time unit and haemodynamic indicators, dopplerogrāfij and spectral study 1 0 26.20 26.20 9.16.
external breathing fundamentals (VC, and Tiffn with the index) discovery and analysis study 2.39 1 0 2.39 10.
Physical medicine 10.1.
Galvanic study 1 0 2.05 2.05 10.2.
medicine electrophoresis study 1 0 2.40 2.40 10.3.
are modulated sinusoidal current (SMS) 1 study 2.05 0 2.05 10.4.
are modulated sinusoidal current (SMS) forēz 1 the examination 2.65 0 2.65 10.5.
cavities electrophoresis study 2.30 0 1 2.30 10.6.
darsonvalizācij 1 the examination 1.79 0 1.79 10.7.
a study of ultraīsviļņ therapy 1 0 1.43 1.43 10.8.
viļņterapij inches (monoplane) 1 study 1.37 0 1.37 10.9.
inch viļņterapij (biplane) 1 study 1.60 0 1.60 10.10.
decimetre viļņterapij (monoplane) 1 study 1.40 0 1.40 10.11.
decimetre viļņterapij (biplane) 1 study 1.60 0 1.60 10.12.
study of the ultrasonic therapy 1 0 10.13 3.20 3.20.
fonoforēz 1 the examination 3.35 0 3.35 10.14.
a changing magnetic field therapy study 1.35 0 1 1.35 10.15.
ultraviolet irradiation of 1 study (de) agea 2.05 2.05 0.
solarium (face) 10 min. ** 1 session 0.90 0.16 1.06 10.17.
solarium (face) 20 min ** 1 session 1.15 0.21 1.36 10.18.
solarium (face) 30 min * session 1 1.35 0.24 1.59 favoured areas.
inhalation 0 session 1 2.05 2.05 10.20.
massage with the massage machine for 10 mins.
1 session 0 0.65 0.65 10.21.
massage with the massage machine 20 min.
1 session 0 1.35 10.22 1.35.
massage with massage apparatus for 30 min.
1 session 0 1.70 1.70 10.23.
paraffin-ozokerite therapy procedure 3.60 1 0 3.60 10.24.
laser therapy-20 min.
1 session 0 2.17 2.17 10.25.
laser treatment for 30 min.
1 session 0 2.80 2.80 10.26.
kriodestrukcij session 1 0 2.20 2.20 10.27.
laser therapy for 5 min.
1 session 0 0.68 0.68 10.28.
laser therapy for 10 min.
1 session 1.00 0 1.00 notes.
1. Value added tax does not apply, in accordance with the law "on value added tax" article 6, first paragraph, point 9.1.
2. The service provides patients the infection. "
Prime Minister i. Godmanis Health Minister i. Morris Editorial Note: rules shall enter into force on 26 July 2008.